Objective To investigate the inhibitory effect of sorafenib in combination with cisplatin (DDP)
on the proliferation of hepatocellular carcinoma cells and explore the molecular …

Objective To investigate the anti-cancer efficacy and mechanism of sorafenib and 5-
fluorouracil (5-FU) therapy in vitro using the HCC cell line MHCCLM3. Methods The effects …

HepG2 cells were treated with different concentrations of sorafenib or adriamycin alone or
their combination to investigate the inhibitory effect of sorafenib in combination with …

Objective To investigate the inhibitory effect of sorafenib in combination with arsenic trioxide
(As2O3) on hepatocellular carcinoma cells and explore the mechanisms of the synergetic …

Methods BEL-7402 cells were treated with sorafenib or paclitaxel alone or in three different
schedules: sorafenib was give prior to, after, or simultaneously with paclitaxel. The half …

HepG2 cells were exposed to sorafenib, irinotecan, and oxaliplatin and then subjected to
MTT assay to determine chemosensitivity. Flow cytometry was used to examine cell cycle …

Sorafenib is currently the standard chemotherapy drug for treatment of advanced
hepatocellular carcinoma (HCC). But its efficacy requires improvement, it is imperative to …

The treatment responses of sorafenib in hepatocellular carcinoma are modest which may be
due to different characteristics of cancer cells or insufficient therapeutic concentrations. This …

To suppress the invasion of hepatocellular carcinoma (HCC) cells into surrounding
connective tissues during metastasis, we investigated the usefulness of sorafenib. In order to …

Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …